CA2420032A1 - Peptide a administration per os - Google Patents

Peptide a administration per os Download PDF

Info

Publication number
CA2420032A1
CA2420032A1 CA002420032A CA2420032A CA2420032A1 CA 2420032 A1 CA2420032 A1 CA 2420032A1 CA 002420032 A CA002420032 A CA 002420032A CA 2420032 A CA2420032 A CA 2420032A CA 2420032 A1 CA2420032 A1 CA 2420032A1
Authority
CA
Canada
Prior art keywords
proliposome
drug
water
preparation
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002420032A
Other languages
English (en)
Inventor
Hack-Joo Kim
Heung-Man An
Min-Jong Cha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyundai Pharm Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2420032A1 publication Critical patent/CA2420032A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un proliposome de médicament à base de peptidyle et des préparations entériques contenant ledit proliposome. Pour obtenir ce proliposome, on dissout le médicament à base de peptidyle avec un phospholipide dans un solvant organique, puis on recouvre la solution ainsi obtenue de chitosane hydrosoluble. Ce système d'administration per os de peptide faisant intervenir le proliposome et les préparations entériques selon l'invention permet d'augmenter considérablement la stabilité et la biodisponibilité des médicaments à base de peptidyle.
CA002420032A 2000-08-11 2000-08-11 Peptide a administration per os Abandoned CA2420032A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2000/000892 WO2002013782A1 (fr) 2000-08-11 2000-08-11 Peptide a administration per os

Publications (1)

Publication Number Publication Date
CA2420032A1 true CA2420032A1 (fr) 2002-02-21

Family

ID=19198254

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002420032A Abandoned CA2420032A1 (fr) 2000-08-11 2000-08-11 Peptide a administration per os

Country Status (6)

Country Link
EP (1) EP1311239A4 (fr)
JP (1) JP2004506003A (fr)
CN (1) CN1479609A (fr)
AU (1) AU2000264796A1 (fr)
CA (1) CA2420032A1 (fr)
WO (1) WO2002013782A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114010801A (zh) * 2021-11-16 2022-02-08 上海理工大学 一种l-抗坏血酸棕榈酸酯修饰的小分子肽脂质体及其制备与应用
CN114081963A (zh) * 2021-11-16 2022-02-25 上海理工大学 一种提高活性肽生物利用度的纳米载体及其制备与应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6761901B1 (en) * 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
US8658202B2 (en) 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
WO2003059288A2 (fr) 2002-01-09 2003-07-24 Enzrel, Inc. Administration medicamenteuse par liposomes de composes anti-inflammatoires, antioxydants, aromatiques ou polycycliques
CN100371018C (zh) * 2003-06-12 2008-02-27 刘青松 降钙素组合物
JP4669665B2 (ja) * 2004-04-12 2011-04-13 正彦 阿部 細胞毒性のないポリカチオン修飾リポソームおよびその製造方法
WO2006062506A1 (fr) * 2004-12-03 2006-06-15 Enzrel, Inc. Administration de composes antioxydants ou anti-inflammatoires au moyen d'un medicament liposomal enrobe de chitosane
JP2008179563A (ja) * 2007-01-24 2008-08-07 Cosmo Shokuhin Kk 有用リン脂質組成物を含む機能性素材及び機能性食品
WO2009149537A1 (fr) * 2008-06-12 2009-12-17 Christine Allen Mélange polymère-lipide injectable
AU2010260211B2 (en) 2008-12-22 2016-04-21 Acerus Pharmaceuticals USA, LLC Safe desmopressin administration
CN103127003B (zh) * 2013-03-19 2014-05-07 广东彼迪药业有限公司 一种奥美拉唑肠溶微丸、胶囊及其制备方法
CN105902400B (zh) * 2016-06-17 2019-10-11 四川百奥可生物科技有限责任公司 一种包裹生物酶的微粒及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0143949B1 (fr) * 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Composition pharmaceutique contenant de l'urokinase
ES2130056B1 (es) * 1997-01-16 2000-02-01 Lipotec Sa Un nuevo preparado farmaceutico para mejorar la biodisponibilidad oral de drogas de dificil absorcion.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114010801A (zh) * 2021-11-16 2022-02-08 上海理工大学 一种l-抗坏血酸棕榈酸酯修饰的小分子肽脂质体及其制备与应用
CN114081963A (zh) * 2021-11-16 2022-02-25 上海理工大学 一种提高活性肽生物利用度的纳米载体及其制备与应用
CN114081963B (zh) * 2021-11-16 2023-09-26 上海理工大学 一种提高活性肽生物利用度的纳米载体及其制备与应用
CN114010801B (zh) * 2021-11-16 2023-09-26 上海理工大学 一种l-抗坏血酸棕榈酸酯修饰的小分子肽脂质体及其制备与应用

Also Published As

Publication number Publication date
EP1311239A4 (fr) 2005-06-22
AU2000264796A1 (en) 2002-02-25
JP2004506003A (ja) 2004-02-26
WO2002013782A1 (fr) 2002-02-21
CN1479609A (zh) 2004-03-03
EP1311239A1 (fr) 2003-05-21

Similar Documents

Publication Publication Date Title
DE60038097T2 (de) Feste orale dosierungsform enthaltend einen resorptionsverstärker
CA2420032A1 (fr) Peptide a administration per os
RU2493868C2 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ
JP2015155433A (ja) ペプチドの組成物及びその調製方法
US6824790B2 (en) Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
JP6568095B2 (ja) プロ酵素及び酵素の混合物を含む医薬組成物
CA3113240C (fr) Composition d'alcaloide psychoactif transmucosal et preparation connexe
CN108635375A (zh) 预防或治疗肝病和肝纤维化及改善肝功能的熊胆粉及用途
CN108578433A (zh) 用于预防或治疗胆结石症胆囊炎和改善胆囊功能的熊胆粉
CA2040237A1 (fr) Produits pharmaceutiques a base de peptide liposomique a action prolongee, et leurs procedes de preparation
CN101340882B (zh) 含有药物的蜡基质粒子的制造方法、用于该方法的挤出机、及含有西洛他唑的缓释制剂
CN104093400A (zh) 稳定的无定形雷特格韦钾盐预混料及其制备方法
CN104042574B (zh) 一种含有更昔洛韦的冻干药物组合物
KR20120138908A (ko) 엔테카비르를 함유하는 미립구 및 이의 제조방법
US20060099243A1 (en) Liposome drug delivery
KR20030064742A (ko) 펩타이드성 약물의 경구용 제제
CN102440959B (zh) 一种匹多莫德脂质体固体制剂
CN106176632B (zh) 一种注射用甲泼尼龙琥珀酸钠组合物
Kadhim et al. PREPARATION AND CHARACTERIZATION OF EZETIMIBE FREEZE-DRIED TABLETS USING ZYDIS® TECHNOLOGY
KR20130110326A (ko) 칼시토닌의 경구투여용 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead